Lung cancer is a malignant tumor with the highest incidence and mortality in China. Liquid biopsy offers advantages such as speed,non-invasiveness and repeatability over traditional tissue biopsy,making it of value in precision medicine and treatment decision for non-small cell lung cancer(NSCLC). This review provides a brief overview of liquid biopsy in screening,early diagnosis,treatment and prognosis evaluation and resistance surveillance. In the future,new technology of liquid biopsy needs to be further improved for sensitivity and specificity,and standardized processes and reference intervals need to be established. Prospective clinical trials also need to be conducted before its clinical transformation.